全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Laura Díaz-Gil , Alberto Ocaña , Atanasio Pandiella
来源:[J].Cancer Letters(IF 4.258), 2020, Vol.470, pp.161-169
摘要:Abstract(#br)Small molecule inhibitors (TKIs) of HER2 have demonstrated clinical benefit in HER2-positive breast tumors. One of them, lapatinib, is used once advanced tumors become refractory to the HER2 antibody trastuzumab. Another one, neratinib, has shown benefit in high-risk...
作者:Alberto Ocaña , Eitan Amir , Atanasio Pandiella
来源:[J].Breast Cancer Research(IF 5.872), 2020, Vol.22 (25), pp.646-674
摘要:Abstract(#br)Background(#br)There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). Methods(#br)Through a literature-based ap...
作者:Alberto Ocaña , Sara García-Alonso ...
来源:[J].Trends in Pharmacological Sciences(IF 9.25), 2018
摘要:The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.
作者:... Joaquín Arribas , Alberto Ocaña , Atanasio Pandiella
来源:[J].Cancer Letters(IF 4.258), 2019, Vol.453, pp.34-44
摘要:Abstract(#br)The appearance of resistance to the anti-HER2 targeted drug trastuzumab constitutes, nowadays, an important challenge in the oncology clinic. To fight such resistance, we searched for potential vulnerabilities in cells resistant to that drug. To that end, we used cel...
作者:... Atanasio Pandiella , Eitan Amir , Alberto Ocaña
来源:[J].Cancer Treatment Reviews(IF 6.024), 2019, Vol.77, pp.11-19
摘要:Abstract(#br)Introduction(#br)Identification of membrane proteins expressed exclusively on tumor cells is a goal for cancer drug development. The receptor tyrosine kinase-like orphan receptor type 1 and 2 (ROR1/2), are type-I transmembrane proteins expressed in cancer but no...
作者:... Habeeb Majeed , Alberto Ocaña , Eitan Amir
来源:[J].Cancer Treatment Reviews(IF 6.024), 2018
摘要:Abstract(#br)Background(#br)Many adjuvant breast cancer trials have observed smaller than anticipated differences between experimental and control groups. Accurate estimation of the absolute benefits of treatment is essential for the planning of clinical trials.(#br)Methods(#br)W...
作者:Alberto Ocaña , Boštjan Šeruga ...
来源:[J].Experimental and Molecular Pathology(IF 2.128), 2017, Vol.102 (3), pp.455-474
摘要:Abstract(#br)Telomere length (TL) has been associated with several health conditions including cancer. To quantify the effect of TL on outcomes in malignancies and explore the role of type of TL measurement we conducted a librarian-led systematic search of electronic databas...
作者:... Atanasio Pandiella , Balázs Győrffy , Alberto Ocaña
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.12 (5)
摘要:Most patients with early stage triple negative breast cancer (TNBC) receive adjuvant chemotherapy. Activation of the immune system is associated with tumor response and may help identify TNBC with favorable outcome.Gene expression data were obtained from the GEO Dataset GDS2250/G...
作者:Alberto Ocaña , Eitan Amir ...
来源:[J].Cancer Treatment Reviews(IF 6.024), 2013, Vol.39 (1), pp.68-76
摘要:Abstract(#br)Dysfunction of protein kinases has been associated with the development of the various molecular subtypes of breast cancer. The best example is the known role of HER2 in the tumorigenesis of a proportion of breast tumors. In this article, we review the state of the a...
作者:Alberto Ocaña , Gabriel N. Hortobagyi , Francisco J. Esteva
来源:[J].Clinical Breast Cancer(IF 2.422), 2006, Vol.6 (6), pp.495-504
摘要:Abstract(#br)Breast cancer is one of the most common malignancies in the Western world. Chemotherapy improves disease-free survival (DFS) and overall survival (OS) rates in women with early-stage breast cancer. Although anthracycline-and taxane-based regimens are considered ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×